BevCanna Enterprises

CASSAVA SCIENCES NASDAQSAVA STOCK QUOTE

https://www.cassavasciences.com/

LATEST NEWS FROM CASSAVA SCIENCES

Cassava Sciences Reports Second Quarter 2021 Financial Results

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease

Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam

Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference

Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease

Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release

Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference

Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors

Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer’s Disease

Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease

Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum

Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

Cassava Sciences to Present at SVB Leerink Global Healthcare Conference

Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease

Cassava Sciences Announces Closing of $200 Million Registered Direct Offering